Treating cryptococcal meningitis in people with HIV
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a positive test for cryptococcal meningitis in your spinal fluid.
- You are living with HIV.
- You are 18 years or older.
- You are willing to have lumbar punctures (spinal taps) as part of this trial.
- You have not had more than 2 doses of antifungal treatment for meningitis in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This study tests whether a shorter course of an antifungal drug (fluconazole) plus earlier HIV treatment is safe and works as well as the standard approach for people with HIV who have a low level of cryptococcal antigen in their blood. It aims to prevent a serious fungal infection from developing.
This study tests whether giving an immune checkpoint inhibitor (a drug that helps your immune system fight infections) can help treat opportunistic infections in people with AIDS that are hard to get rid of. It aims to see if the treatment is safe and works for these stubborn infections.
This study tests a new combo pill for HIV (ainuovirine, lamivudine, and tenofovir) against a standard pill (efavirenz, lamivudine, and tenofovir) in people who have both HIV and tuberculosis. It aims to find a treatment that works well and has fewer side effects.
This trial compares two antifungal medicines to treat talaromycosis, a serious fungal infection common in people with HIV. It tests whether a shorter course of treatment with two medicines is as good as the standard approach, which may help reduce side effects and hospital time.
This trial tests a one-time high dose of an antifungal medicine (liposomal amphotericin B) combined with a standard HIV treatment (B/F/TAF) for people with HIV who also have talaromycosis, a serious fungal infection. The goal is to see if this approach is safe and effective.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.